Japan Tobacco
As of the edition of 20 October 2026, Japan Tobacco runs 12 drugs, 11 of them marketed; it is on route A at 0 targets and on route B at 2 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 11 |
| Active | 1 |
| Total | 12 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Tenofovir disoproxil | none listed | 0 |
| Emtricitabine | Ends 2032 (patent) | 0 |
| Tenofovir alafenamide | Ends 2032 (patent) | 0 |
| Tenofovir anhydrous | none listed | 0 |
| Cobicistat | Ends 2032 (patent) | 0 |
| Histamine | none listed | 3 |
| Elvitegravir | Ends 2026 (patent) | 0 |
| Tapinarof | Ends 2038 (patent) | 2 |
| Delgocitinib | Ends 2031 (patent) | 4 |
| Ferric citrate anhydrous | none listed | 0 |
| Enarodustat | none listed | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 2 targets.
All 2 rows on route A or B
In the product2 company-target rows on route A or B; 0 are not shown here, and no score is.
See all 2 targets where Japan Tobacco needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Inherited and neonatal: 1 trials led
- Nutrition and metabolism: 1 trials led